BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20688100)

  • 1. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
    Kennett GA; Clifton PG
    Pharmacol Biochem Behav; 2010 Nov; 97(1):63-83. PubMed ID: 20688100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drug targets for the treatment of obesity.
    Powell AG; Apovian CM; Aronne LJ
    Clin Pharmacol Ther; 2011 Jul; 90(1):40-51. PubMed ID: 21654742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the pathophysiology and pharmacological treatment of obesity.
    Chugh PK; Sharma S
    J Clin Pharm Ther; 2012 Oct; 37(5):525-35. PubMed ID: 22462645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting thermogenesis and related pathways in anti-obesity drug discovery.
    Clapham JC; Arch JR
    Pharmacol Ther; 2011 Sep; 131(3):295-308. PubMed ID: 21514319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy for obesity--current status and future hopes.
    Bray GA
    Med Clin North Am; 2007 Nov; 91(6):1225-53, xi. PubMed ID: 17964918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug treatment of obesity--current situation and perspectives].
    Hainer V
    Cas Lek Cesk; 2010; 149(11):513-9. PubMed ID: 21391349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical review of the cannabinoid receptor as a drug target for obesity management.
    Akbas F; Gasteyger C; Sjödin A; Astrup A; Larsen TM
    Obes Rev; 2009 Jan; 10(1):58-67. PubMed ID: 18721231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiobesity effects of melanin-concentrating hormone receptor 1 (MCH-R1) antagonists.
    Cheon HG
    Handb Exp Pharmacol; 2012; (209):383-403. PubMed ID: 22249825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Well-being of obese individuals: therapeutic perspectives.
    Chaput JP; Tremblay A
    Future Med Chem; 2010 Dec; 2(12):1729-33. PubMed ID: 21428796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incretin pathway as a new therapeutic target for obesity.
    Barber TM; Begbie H; Levy J
    Maturitas; 2010 Nov; 67(3):197-202. PubMed ID: 20655673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the prognosis for new centrally-acting anti-obesity drugs?
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2012 Jul; 63(1):132-46. PubMed ID: 22313529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
    Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
    Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
    Correia ML; Haynes WG
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):643-60. PubMed ID: 16083333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
    Baghdadli A; Gonnier V; Aussilloux C
    Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR; Dhakal-Karki S; Dunican KC
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the discovery and development of new agents for the treatment of obesity.
    Staten MA
    Clin Pharmacol Ther; 2007 May; 81(5):753-5. PubMed ID: 17377527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medications for obesity: mechanisms and applications.
    Bray GA
    Clin Chest Med; 2009 Sep; 30(3):525-38, ix. PubMed ID: 19700050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.
    Jackson VM; Price DA; Carpino PA
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1055-66. PubMed ID: 25000213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.